

1 **Assessing the Impact of COVID-19 on Multimorbidity: Insights from Structural**
2 **Equation Modeling in Colombia**

3 Porras-Ramírez A^{*1,2}, Rico-Mendoza A¹, Campos-Maya A¹, Cardenas-Sanchez J³, Penagos-
4 Lopez D¹, Gomez-Puentes A¹, Delgado-Quiroz N¹, Guarín-Muñoz L¹, Ortiz-Elejalde J¹

5 1. Group of Community Medicine and Public Health, Universidad El Bosque, Bogota,
6 Colombia

7 2. Epidemiology Coordination, Los Cobos Medical Center, Bogota, Colombia

8 3. Subred integrada de servicios de salud Suroccidente, E.S.E., Bogota, Colombia

9

10 * CORRESPONDING AUTHOR:

11 Alexandra Porras-Ramirez

12 ORCID: 0000-0002-0800-1388

13 Address: Ak. 9 #131a-40, Usaquén, Bogotá, Cundinamarca. Postal Code: 110121

14 Mail: rporrasalexandra@unbosque.edu.co

15

16

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

17 Abstract:

18 Background: Multimorbidity, the coexistence of multiple chronic diseases, poses significant
19 challenges for healthcare systems worldwide. This study aims to assess the situation of
20 multimorbidity in Colombia using structural equation models and to characterize multimorbidity
21 by sex, age group, region, and health insurance regime between 2019 and 2023.

22 Methods: We conducted a cross-sectional analytical study utilizing data from the Individual
23 Health Service Provision Registry (RIPS) and other national databases, including the Unit of
24 Payment by Capitation (UPC) Sufficiency Study Database. Structural equation models were
25 employed to identify and analyze multimorbidity clusters among patients with two or more
26 chronic diseases.

27 Results: The study revealed a multimorbidity prevalence of 61.5% in the general population.
28 Hypertension emerged as the most prevalent chronic condition, frequently associated with
29 diabetes and chronic kidney disease. Multimorbidity was more common in women and
30 individuals affiliated with the contributory insurance regime. The study also identified
31 significant variations in multimorbidity prevalence across different regions and age groups.

32 Conclusions: Multimorbidity is a prevalent issue in Colombia, with substantial variations by
33 sex, age, and insurance regime. These findings underscore the need for tailored healthcare
34 strategies to address the diverse needs of multimorbid patients. The results provide critical
35 insights for health service planning and management, emphasizing the importance of
36 continued research and policy development to mitigate the burden of chronic diseases and
37 multimorbidity in Colombia.

38 Keywords: Structural Equation Modeling, Multimorbidity, chronic diseases, databases.

39 Background

40 Structural equation models (SEMs) are advanced analytical tools that estimate the effects and
41 relationships between multiple variables, offering greater flexibility than traditional regression
42 models (1). Combining elements of factor analysis and path analysis, SEMs model both direct
43 and indirect effects among variables, making them particularly valuable in health research
44 where complex interrelationships are common (2). A key strength of SEMs is their ability to
45 construct latent variables, enhancing the reliability and validity of the models by capturing
46 underlying constructs that traditional regression models might miss (Byrne, 2010). SEMs also
47 allow for the simultaneous estimation of multiple relationships, providing a comprehensive
48 understanding of the data.

49 In recent years, the prevalence and burden of multimorbidity—the presence of two or more
50 chronic conditions—have gained increasing attention globally. Multimorbidity poses significant
51 challenges for healthcare systems in terms of healthcare planning, resource allocation, and
52 patient management (3). Understanding the distribution and determinants of multimorbidity in
53 Colombia is critical for effective health policy and intervention design.

54 This study aims to assess multimorbidity in Colombia by characterizing the multimorbidity
55 patterns of individuals affiliated with the General System of Social Security in Health (SGSSS)
56 from 2019 to 2023. Utilizing SEMs to analyze multimorbidity clusters, the study examines
57 variations by sex, age group, region, and insurance regime, providing insights into the complex
58 interactions of chronic diseases and informing health service planning and policy development
59 in Colombia (4 - 6).

60 Colombian Health System and Affiliation Regimes

61 Colombia's health system, structured under the General System of Social Security in Health
62 (SGSSS) established by Law 100 of 1993, aims to provide universal health coverage to all
63 Colombians. The SGSSS operates through two main insurance regimes: the contributory
64 regime and the subsidized regime. This dual-regime structure promotes equity in healthcare
65 access by offering different pathways to health insurance based on financial ability, ensuring
66 that all citizens, regardless of economic status, can receive necessary medical care. This
67 approach helps reduce health disparities and improve overall public health in the country.

68 Prevalence of Hypertension and Diabetes and healthcare utilization

69 Before 2012-2019, hypertension and diabetes prevalence in Colombia was stable at 20.5%,
70 indicating consistent chronic disease management and healthcare access. During COVID-19,
71 prevalence surged to 24.3% in 2021 due to severe COVID-19 risks, increased diagnosis, and
72 healthcare disruptions worsening chronic conditions.

73 SEM analysis showed that prior to the pandemic, patients with hypertension and diabetes had
74 6.8 healthcare visits annually and a 78% medication adherence rate. During COVID-19, visits
75 decreased to 5.4 in 2020, with adherence at 65%, due to infection fears and healthcare strain.
76 By 2023, visits increased to 6.2 yearly, adherence improved to 78%, aided by healthcare
77 adaptations and telemedicine, as restrictions eased.

78 Hospitalization Rates

79 Before the COVID-19 pandemic (2012-2019), hospitalization rates for hypertension and
80 diabetes complications were around 25 per 1000 patients. This rate increased to 38 per 1000
81 in 2020 due to the severe impact of COVID-19 and delayed care. By 2023, rates declined to
82 30 per 1000, indicating improvements in chronic disease management, healthcare access,
83 vaccination efforts, and effective COVID-19 treatments.

84 Methods

85 Study Design

86 This study is an exploratory ecological investigation aimed at defining multimorbidity clusters
87 in Colombia and characterizing these clusters according to age group, sex, region, and
88 affiliation with the General System of Social Security in Health (SGSSS).

89 Study Period

90 The analysis covers data collected from 2019 to 2023.

91 Data Sources

92 The primary sources of data for this study include:

93 1. Individual Health Service Provision Registry (RIPS): This registry contains detailed
94 records of health services provided, including identification of health service providers, users
95 receiving the services, types of services provided, and diagnoses. The RIPS database
96 categorizes data into identification data, health service data, and reason for service data.

97 2. Unit of Payment by Capitation (UPC) Sufficiency Study Database: This database
98 contains EPS-provided data, quality-checked by the Ministry of Health and Social Protection.
99 It covers healthcare expenses and technologies categorized into activities, interventions,
100 procedures, medications, devices, and supplies.

101 3. Additional Databases:

102 • Vital Statistics Database from DANE

103 • Unique Affiliate Database (BDUA)

104 • Reimbursement Database

105 • MIPRES Database

106 • High-Cost Account Database

107 • SIVIGILA Database

108 Population and Sample

109 The study population consists of individuals affiliated with the contributory and subsidized
110 regimes of SGSSS during the study period. The units of observation are patients with two or
111 more chronic diseases reported in the sufficiency and RIPS databases (7).

112 Variables

113 Key variables include age, sex, department, prevalence of chronic conditions, disability status,
114 and health service usage. The presence of chronic conditions is treated as a binary variable
115 in the structural equation model.

116 Analytical Methods

117 1. Systematic Literature Review: A comprehensive literature review was conducted to
118 establish definitions of interest, identify clusters from multimorbidity studies in other countries,
119 and determine the methodology for identifying and prioritizing disease clusters.

120 2. Selection and Grouping of ICD-10 Diagnoses: Diagnoses from the International
121 Classification of Diseases 10th Revision (ICD-10) were classified to identify chronic diseases.
122 An agreement exercise between the World Bank and Ministry of Health and Social Protection
123 teams facilitated the grouping of diseases to identify multimorbidity clusters.

124 3. Age Group Definition: The population was divided into the following age groups for
125 analysis:

- 126 • 0 to 17 years: Childhood and Adolescence
- 127 • 18 to 59 years: Adulthood
- 128 • 60 years and older: Elderly

129 4. Structural Equation Modeling (SEM): SEM calculated crude prevalence of global and
130 stratified multimorbidity by age and sex. It estimated causal relationships from statistical data
131 and qualitative assumptions, calculating frequencies of all possible multimorbidity patterns.
132 Significance was set at $\alpha = 0.005$, analyzed using Stata Statistical Software (version 14).

133 5. Factor Analysis: Factor analysis was employed to reduce and summarize the data,
134 calculating latent dimensions (factors) to explain relationships among variables. The simplest
135 factorial structure was extracted for easier interpretation.

136 Statistical Analysis

137 The SEM was validated against empirical data samples to determine if the data fit the
138 hypothesized model, with statistical significance assessed using a chi-square test (p-value of
139 $X^2 = 0.0023$). Factor analysis was used to identify and interpret underlying dimensions of
140 multimorbidity.

141 This methodology ensures a comprehensive and rigorous approach to understanding
142 multimorbidity in the Colombian population, providing valuable insights for healthcare policy
143 and management.

144 Results

145 For this study, a structural equation was designed considering variables such as age, sex,
146 department, prevalence, disability, and service usage to identify and prioritize the main
147 clusters of chronic diseases affecting health service delivery during the analysis period.

148 Data for the structural equation model came from insurers of Colombia's contributory and
149 subsidized regimes, using the SGSSS sufficiency study database from 2019 to 2023. It
150 covered the general population, segmented by age groups (0-17, 18-59, and 60+), sex,
151 insurance regime, and department. Coverage details by insurance regime are provided in
152 Table 1.

153 Proportion of Patients with Multimorbidity

154 From 2019 to 2023, multimorbidity affected 61.5% of the general population, amounting to an
155 annual average of 11,192,469 individuals (8). The distribution of conditions showed 29.1%
156 with two conditions, 11.4% with three, and decreasing percentages with higher numbers of
157 conditions (Table 2).

158 Hypertension was the most prevalent condition across all age groups in the main clusters
159 identified, with an overall prevalence of 41.2% in the general population, increasing with age.
160 The table was constructed using a probability threshold of 0.1, indicating all clusters listed
161 exceeded this probability.

162

163 Distribution of Multimorbidity by Age

164 For the analyzed age groups, it was found that in the 0 to 17 years group, chronic periodontal
165 diseases were most common (65.3%), with multimorbidity at 15.3% annually (838,530
166 individuals). Common clusters included vision disorders and periodontal diseases (probability
167 0.87). Among those aged 18-59, multimorbidity was 33.1% (1,814,074 individuals), with
168 chronic back pain prevalent (65.0%). Common clusters included chronic back pain and
169 periodontal diseases (probability 0.90). In adults over 60, multimorbidity was 51.3% (2,811,541
170 individuals), with hypertension most prevalent (68.7%). Common clusters included
171 hypertension and diabetes (probability 0.96), and hypertension, diabetes, and chronic kidney
172 disease (0.91). Fifty clusters were identified using a probability cutoff of 0.1.

173 Distribution of Multimorbidity by Sex and SGSSS Affiliation

174 From 2019 to 2023, multimorbidity was more prevalent among women (67.3%) and was higher
175 in the contributory insurance regime (58.3%). This reflects greater healthcare utilization by
176 contributory regime patients, who are more represented in the UPC sufficiency database
177 compared to subsidized regime patients (9).

178 Distribution of Multimorbidity by Department

179 The highest prevalence of multimorbidity by department was found in Risaralda, Quindío,
180 Huila, and Magdalena (prevalence proportion higher than 7,000 per 100,000 inhabitants) (Map
181 1).

182 Map 1. Proportion of Multimorbidity Prevalence by Department in Colombia (2019-2023)

183

184 The main clusters of multimorbidity by department are shown in Table 3.

185 The highest frequency of multimorbidity was found in the Eastern region with an average of
186 53.0%, followed by the Coffee Belt region with 45.3%.

187 MIPRES Analysis for 2023 in Patients with Multimorbidity

188 In 2023, MIPRES reviewed prescriptions from 32 EPSs in the subsidized regime (94.0%) and
189 16 EPSs in the contributory regime (88.0%). Nutritional supplements had the highest non-
190 benefit plan prescriptions, totaling 294,624 in 2017. Antioquia, the Coffee Belt, and
191 Bucaramanga's metropolitan area had the highest per-affiliate prescriptions, with lower
192 numbers in Bogotá, the Caribbean region, and the southwestern part of Colombia.

193 The most common cluster, hypertension and diabetes, affected an average of 2,464,885
194 patients annually, with 2,249,504 prescriptions from 8,611 professionals. Departments like
195 Antioquia, Atlántico, Boyacá, Santander, Risaralda, Quindío, Manizales, Cauca, Caldas,
196 Huila, and Valle del Cauca had the highest occurrence of this cluster with non-benefit plan
197 medications.

198 Analysis of a Multimorbidity Cluster Impacted by COVID-19

199 One of the most significant clusters identified in the study was the combination of hypertension
200 and diabetes, which has been notably impacted by the COVID-19 pandemic. Individuals with
201 these conditions are at a higher risk of severe COVID-19, leading to complications such as
202 acute respiratory distress syndrome, multi-organ failure, and increased mortality rates.
203 Additionally, the pandemic has significantly impacted mental health, causing increased stress,
204 anxiety, and depression, which can adversely affect blood pressure and glucose control.

205

206 Stress-related behaviors such as poor diet, lack of exercise, and increased alcohol
207 consumption can further exacerbate these conditions. The data showed that the prevalence
208 of the hypertension and diabetes cluster was particularly high among older adults, who are
209 also more susceptible to severe COVID-19 outcomes. The pandemic has likely increased the
210 burden on this population due to direct health impacts and indirect consequences through
211 healthcare disruptions and socioeconomic stressors (10, 12).

212 The impact of COVID-19 on the multimorbidity cluster of hypertension and diabetes was
213 analyzed using Structural Equation Modeling (SEM). This analysis was conducted to compare
214 the prevalence, healthcare utilization, and outcomes for this cluster before and after the onset
215 of the COVID-19 pandemic.

216 Situation of COVID-19 (2012-2019)

217 Before COVID-19 (2012-2019), Colombia's hypertension and diabetes cluster prevalence was
218 20.5%. Path coefficients were 0.65 for hypertension and 0.55 for diabetes regarding age, and
219 0.45 for hypertension and 0.50 for diabetes regarding healthcare utilization. Patients averaged
220 6.8 annual healthcare visits, a 78% medication adherence rate, and a 25 per 1000
221 hospitalization rate for complications (13).

222 After COVID-19 (2020-2023), the hypertension and diabetes cluster peaked at 24.3% in 2021
223 and declined to 22.1% by 2023. Path coefficients rose to 0.68 for hypertension and 0.58 for
224 diabetes concerning age, and 0.55 and 0.60 for healthcare utilization, respectively. The
225 pandemic increased the burden on older adults, with healthcare utilization dropping to 5.4
226 visits annually in 2020 and rebounding to 6.2 by 2023. Medication adherence fell to 65% in
227 2020, returning to 78% by 2023. Hospitalization rates for complications rose to 38 per 1000
228 patients in 2020 and decreased to 30 per 1000 by 2023.

229

230 The SEM analysis reveals several key findings:

231 The hypertension and diabetes cluster prevalence rose during COVID-19, likely due to
232 exacerbated conditions or improved diagnosis. Healthcare visits and medication adherence
233 dropped significantly in 2020 due to lockdowns, system overload, and patient fears. By 2023,
234 healthcare utilization returned to pre-pandemic levels, indicating recovery in healthcare
235 access and delivery.

236 Hospitalization rates for hypertension and diabetes complications surged in 2020,
237 underscoring heightened patient vulnerability during the pandemic. Subsequent declines
238 suggest improved condition management and the impact of vaccination and better COVID-19
239 treatments.

240 Limitations and Biases

241 This study has limitations: reliance on secondary administrative data may cause
242 misclassification bias; its cross-sectional design limits causal inference; potential selection
243 bias in the RIPS database may omit some health interactions, especially among those with
244 limited healthcare access; and overrepresentation of contributory regime patients in the UPC
245 database may affect findings. (14,15).

246 Residual confounding from unmeasured variables like lifestyle, genetics, and environmental
247 exposures may affect observed associations. The findings' generalisability is limited by
248 differences in healthcare systems, demographics, and disease prevalence, requiring further
249 research in diverse settings and populations. (16)

250 Conclusions

251 Chronic diseases and their associations are rising in Colombia due to demographic transitions,
252 improved living conditions, new health technologies, and better acute disease treatments,
253 leading to lower infant mortality and increased life expectancy. Multimorbidity is more common
254 in women and those in the contributory regime, likely due to better health-seeking behaviors,
255 treatment adherence, healthcare access, and higher socioeconomic status.

256 Using the WHO's definition of multimorbidity, this study classified chronic diseases into 123
257 groups using ICD-10 diagnoses. Analytical methods included Cluster Analysis, SEM, and
258 Latent Class Analysis across multiple databases. Findings showed hypertension as the most
259 frequent chronic condition, aligning with global trends.

260 The prevalence of hypertension and diabetes increased notably during the COVID-19
261 pandemic, attributed to higher risks for severe outcomes and improved diagnosis and
262 reporting. The SEM analysis highlighted significant changes in multimorbidity patterns due to
263 the pandemic, underscoring the need for resilient healthcare systems that can adapt to crises
264 while maintaining essential chronic disease management services. The study emphasized the
265 importance of standardized research approaches to improve comparability and identified
266 hypertension as a critical public health issue. (16, 17)

267 The study highlights a high multimorbidity prevalence, impacting health service planning and
268 management. It identifies key chronic disease clusters needing targeted interventions for
269 improved health outcomes and reduced healthcare system burden. Continued research and
270 policy development are crucial to tackle Colombia's chronic disease challenges effectively.

271 Conflict of interest:

272 All authors declare that they have no conflict of interest in this article.

273 **References**

- 274 1. Ruiz RJ. Structural Equation Modeling: Advanced Methodology for the Health
275 Sciences. *Int J Med Res*. 2010;39(3):215-223.
- 276 2. Byrne. (2010). *Structural Equation Modeling with AMOS. Basic Concepts, Applications,*
277 *and Programming*. Nueva York: Taylor & Francis.
- 278 3. van den Akker M, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity: What's in
279 a name? A review of literature. *Eur J Gen Pract*. 1998;4(2):65-70.
- 280 4. Xu X, Mishra GD, Jones M. Evidence on multimorbidity from definition to intervention:
281 An overview of systematic reviews. *Ageing Res Rev*. 2017;37:53-68.
- 282 5. Violan C, Foguet-Boreu Q, Flores-Mateo G, Salisbury C, Blom J, Freitag M, et al.
283 Prevalence, determinants, and patterns of multimorbidity in primary care: A systematic review
284 of observational studies. *PLoS One*. 2014;9(7)
- 285 6. Prados-Torres A, Poblador-Plou B, Calderón-Larrañaga A, et al. Multimorbidity
286 patterns in primary care: Interactions among chronic diseases using factor analysis. *PLoS*
287 *One*. 2014;9(2)
- 288 7. Thavorn K, Maxwell CJ, Gruneir A, et al. Effect of socio-demographic factors on
289 multimorbidity among older adults: A population-based study. *BMC Geriatr*. 2017;17(1):13.
- 290 8. Onder G, Palmer K, Navickas R, et al. Time to face the challenge of multimorbidity: A
291 European perspective from the joint action on chronic diseases and promoting healthy aging
292 across the life cycle (JA-CHRODIS). *Eur J Intern Med*. 2015;26(3):157-159.

- 293 9. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and
294 implications for health care, research, and medical education: A cross-sectional study. *Lancet*.
295 2012;380(9836):37-43.
- 296 10. Bekelman DB, H. E. (2007). Symptoms, Depression, and Quality of Life in Patients
297 With Heart Failure. . *J Card Fail.* , 13:643–648. Borenstein M, H. L. (2009.). Introduction to
298 meta-analysis Londres. . London:Wiley.
- 299 11. De Bruin SR, H. R. (2011). Impact of disease management programmes on health
300 care expenditures for patients with diabetes, depression, heart failure or chronic obstructive
301 pulmonary disease: a systematic review of the literature. *Health Policy* ,101:5–21. Whitty CJM,
302 MacEwen C, Goddard A, et al. Rising to the challenge of multimorbidity. *BMJ*. 2020;368.
- 303 12. American Geriatrics Society Expert Panel on the Care of Older Adults. (2012.). Patient-
304 Centered Care for Older Adults with Multiple Chronic Conditions: A Stepwise Approach from
305 the American Geriatrics Society. *J Am Geriatr Soc* ,60:1957–1968.
- 306 13. Boyd CM, F. M. (2010). Future of multimorbidity research: how should understanding
307 of multimorbidity inform health system design? . *Public Health Rev.* ,32(2):451–74.
- 308 14. Charlson ME, P. P. (1987). A new method of classifying prognostic comorbidity in
309 longitudinal studies: development and validation. *J Chronic Dis* , vol. 40 (pg. 373-383).
- 310 15. Broemeling AM, W. D. (2008). Population patterns of chronic health conditions, co-
311 morbidity and healthcare use in Canada: implications for policy and practice. *Healthc Q*, vol.
312 11 3(pg. 70-76).
- 313 16. Lemmens K, L. L. (2011). Chronic care management for patients with COPD: a critical
314 review of available evidence. *Journal of Evaluation in Clinical Practice* , 19(5):734–52.

- 315 17. Garin N, O. B.-M. (2014). Impact of multimorbidity on disability and quality of life in the
316 Spanish older population. . PLoS One. 9(11):e111498.

Table 1. Coverage by Insurance Regime in the Sufficiency Data (2019 - 2023)

Regime	2019	2020	2021	2022	2023
Contributory	19,957,738	20,150,266	20,750,202	21,295,724	21,713,023
Subsidized	22,605,295	22,669,543	22,998,377	22,016,310	21,176,856
Sufficiency (C)	14,041,322	15,153,132	15,936,771	16,550,231	16,801,472
Sufficiency (S)	8,694,001	8,919,836	8,908,969	10,971,130	11,802,194
Coverage (C) %	70.4	75.2	76.8	77.7	77.4
Coverage (S) %	38.5	39.3	39.4	49.8	55.7

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.11.24313500>; this version posted September 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Table 2. Proportion of Patients with Multimorbidity Using Structural Equation in Colombia (2019-2023)

Year	1 Condition	2 Conditions	3 Conditions	4 Conditions	5 Conditions	6 Conditions	7 Conditions	Total Conditions
2019	5,132,523	2,875,456	1,075,517	544,375	136,521	93,253	78,520	9,936,165
%	51.7	28.9	10.8	5.5	1.4	0.9	0.8	1000

Year	1 Condition	2 Conditions	3 Conditions	4 Conditions	5 Conditions	6 Conditions	7 Conditions	Total Conditions
2013	5,118,925	2,928,027	1,096,053	553,536	142,160	96,663	80,887	10,016,251
%	51.1	29.2	10.9	5.5	1.4	1.0	0.8	1000
2014	6,076,510	3,402,977	1,337,729	675,290	204,892	128,601	96,932	11,922,931
%	51.0	28.5	11.2	5.7	1.7	1.1	0.8	1000
2015	6,102,653	3,455,548	1,358,265	684,451	210,531	132,011	99,299	12,042,758
%	50.7	28.7	11.3	5.7	1.7	1.1	0.8	1000
2023	6,128,796	3,508,119	1,378,801	693,612	216,170	135,421	101,666	12,044,240
%	50.9	29.1	11.4	5.8	1.8	1.1	0.8	1000

Table 3. Most Frequent Clusters by Department in Colombia (2019-2023)

Department	Most Frequent Clusters	Probability
Antioquia	Hypertension and Diabetes	0.82
	Prostate Cancer and Hypertension	0.74
	Hypertension and Chronic Kidney Disease	0.72
	Hypertension, Diabetes, and Chronic Kidney Disease	0.71
	Chronic Viral Hepatitis and Malignant Liver Tumors	0.51

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.11.24313500>; this version posted September 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Department	Most Frequent Clusters	Probability
Atlántico	Malignant Breast Tumor, Obesity, and Hypertension	0.51
	Chronic Viral Hepatitis and Malignant Liver Tumors	0.50
	Leukaemia and Substance Use Disorders	0.49
	Hypertension and Chronic Kidney Disease	0.70
	Hypertension and Diabetes	0.65
	Thyroid Cancer, Obesity, and Diabetes	0.65
	Hypertension, Diabetes, and Chronic Kidney Disease	0.62
	Prostate Cancer and Hypertension	0.74
Bogotá	Prostate Cancer and Hypertension	0.74
	HIV/AIDS and Tuberculosis	0.64
	HIV/AIDS, Tuberculosis, and Sequelae	0.64
	Colon Cancer and Hypertension	0.62
	Cervical Cancer and Depression	0.52
	Lymphoma and Hypertension	0.52
	Hypertension and Lymphoma	0.52
	Hypertension and Chronic Kidney Disease	0.78
Bolívar	Hypertension and Diabetes	0.71
	Hypertension, Diabetes, and Chronic Kidney Disease	0.65
	Hypertension and Cerebrovascular Diseases	0.61
	Hypertension and COPD	0.66

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.11.24313500>; this version posted September 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Department	Most Frequent Clusters	Probability
	Hypertension and Malignant Stomach Tumors	0.64
	Hypertension, Diabetes, and Chronic Kidney Disease	0.63
	Hypertension and Chronic Kidney Disease	0.62
	Hypertension and Diabetes	0.60
Caldas	Hypertension and Atherosclerosis	0.78
	Hypertension, Diabetes, and Chronic Kidney Disease	0.62
	Hypertension and Diabetes	0.61
	Hypertension and Chronic Kidney Disease	0.60
Caquetá	Hypertension and Diabetes	0.80
	Hypertension and COPD	0.71
	Malignant Breast Tumor, Obesity, and Hypertension	0.51
Cauca	Hypertension and COPD	0.71
	Hypertension and Diabetes	0.65
	HIV/AIDS, Tuberculosis, and Sequelae	0.64
	Hypertension, Diabetes, and Chronic Kidney Disease	0.63
Cesar	Hypertension and COPD	0.72
	COPD and Chronic Periodontal Diseases	0.70
	Hypertension and Malignant Lung Tumors	0.65
Córdoba	Hypertension and Diabetes	0.72

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.11.24313500>; this version posted September 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Department	Most Frequent Clusters	Probability
	Hypertension and COPD	0.65
	Chronic Viral Hepatitis and Nutritional Anemias	0.64
	Hypertension and Lymphoma	0.52
Cundinamarca	Hypertension and Prostate Diseases	0.75
	Hypertension and Diabetes	0.72
	COPD and Chronic Periodontal Diseases	0.71
	Hypertension and Chronic Kidney Disease	0.65
	Hypertension, Diabetes, and Chronic Kidney Disease	0.62
Chocó	Hypertension, Diabetes, and Chronic Kidney Disease	0.78
	Hypertension and Prostate Diseases	0.75
	Hypertension and Diabetes	0.71
	Tuberculosis and Diabetes	0.56
Huila	Hypertension and Diabetes	0.62
	Hypertension, Diabetes, and Chronic Kidney Disease	0.58
	Hypertension and Atherosclerosis	0.71
La Guajira	Hypertension and Atherosclerosis	0.79
	Hypertension, Diabetes, and Chronic Kidney Disease	0.78
	Hypertension and Diabetes	0.71
Magdalena	Hypertension and Diabetes	0.82

Department	Most Frequent Clusters	Probability
	Hypertension and COPD	0.66
	HIV/AIDS, Tuberculosis, and Sequelae	0.64
Meta	Hypertension, Diabetes, and Chronic Kidney Disease	0.74
	Hypertension and Diabetes	0.71
	Hypertension and COPD	0.66
Nariño	Hypertension, Diabetes, and Chronic Kidney Disease	0.74
	Hypertension and Diabetes	0.71
	Hypertension and COPD	0.66
	HIV/AIDS, Tuberculosis, and Sequelae	0.64
Norte de Santander	Hypertension and COPD	0.76
	Prostate Cancer and Hypertension	0.74
	Hypertension and Diabetes	0.71
	HIV/AIDS, Tuberculosis, and Sequelae	0.64
Quindío	Hypertension and Atherosclerosis	0.78
	Hypertension, Diabetes, and Chronic Kidney Disease	0.72
	Hypertension and Diabetes	0.71
	Hypertension and Chronic Kidney Disease	0.69
	HIV/AIDS, Tuberculosis, and Sequelae	0.64
Risaralda	Hypertension and Atherosclerosis	0.78
	Prostate Cancer and Hypertension	0.74

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.11.24313500>; this version posted September 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.11.24313500>; this version posted September 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Department	Most Frequent Clusters	Probability
	Hypertension and Diabetes	0.71
	Thyroid Cancer, Obesity, and Diabetes	0.65
	HIV/AIDS, Tuberculosis, and Sequelae	0.64
Santander	Hypertension and Atherosclerosis	0.78
	Hypertension and COPD	0.76
	Hypertension and Diabetes	0.71
Sucre	Hypertension and Diabetes	0.78
	Hypertension and Atherosclerosis	0.71
	Hypertension and COPD	0.70
	Hypertension and Lymphoma	0.52
Tolima	Hypertension and Diabetes	0.75
	Hypertension and COPD	0.72
	Hypertension and Atherosclerosis	0.71
Valle del Cauca	Hypertension and Diabetes	0.82
	Hypertension and Prostate Diseases	0.75
	Hypertension, Diabetes, and Chronic Kidney Disease	0.71
	Thyroid Cancer, Obesity, and Diabetes	0.65
	HIV/AIDS, Tuberculosis, and Sequelae	0.64
	Leukaemia and Substance Use Disorders	0.49
Arauca	Hypertension and Diabetes	0.82
	Hypertension, Diabetes, and Chronic Kidney Disease	0.71

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.11.24313500>; this version posted September 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Department	Most Frequent Clusters	Probability
Casanare	Hypertension and Diabetes	0.75
	Hypertension, Diabetes, and Chronic Kidney Disease	0.74
	Hypertension and COPD	0.76
Caquetá	Hypertension and COPD	0.76
	Hypertension and Diabetes	0.65
	Cervical Cancer and Depression	0.52
Putumayo	Hypertension and COPD	0.76
	Cervical Cancer and Depression	0.52
	Malignant Breast Tumor, Obesity, and Hypertension	0.51
San Andrés	Thyroid Cancer, Obesity, and Diabetes	0.65
	Hypertension and Lymphoma	0.52
Amazonas	Prostate Cancer and Hypertension	0.74
	Malignant Breast Tumor, Obesity, and Hypertension	0.51
Guainía	Hypertension and COPD	0.76
	Hypertension and Diabetes	0.75
	Hypertension, Diabetes, and Chronic Kidney Disease	0.74
	Cervical Cancer and Depression	0.52
	Malignant Breast Tumor, Obesity, and Hypertension	0.51

Department	Most Frequent Clusters	Probability
Guaviare	Hypertension and Diabetes	0.75
	Malignant Breast Tumor, Obesity, and Hypertension	0.51
	Chronic Viral Hepatitis and Malignant Liver Tumors	0.50
Vaupés	Hypertension and Diabetes	0.81
	Malignant Breast Tumor, Obesity, and Hypertension	0.51
	Leukaemia and Substance Use Disorders	0.49
Vichada	Hypertension, Diabetes, and Chronic Kidney Disease	0.74
	Hypertension and Diabetes	0.71
	Leukaemia and Substance Use Disorders	0.49

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.11.24313500>; this version posted September 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Table 4: Prevalence and Impact of Hypertension and Diabetes Cluster During COVID-19 (2019-2023)

Year	Prevalence (%)	COVID-19 Hospitalizations (per 1000)	COVID-19 Mortality Rate (%)	Vaccination Coverage (%)
2019	20.5	-	-	-
2020	22.8	45	15.3	12
2021	24.3	50	14.7	65
2022	23.7	38	12.2	78
2023	22.1	30	10.5	82

Map 1. Proportion of Multimorbidity Prevalence by Department in Colombia (2019-2023)

